Cognitive Dysfunction in Psychiatric Disorders
Cognitive dysfunction does not just signify poor memory, the range of cognitive impairment is broader and more complex.
Basis of Cognitive Impairment in Disease
- Cerebral circuits and cellular cascades controlling cognition
Cognition can be best understood in terms of complex networks operating over multiple temporal scales and incorporating diverse dimensions: from cellular cascades to cerebral circuits and, ultimately, society. Specific domains such as executive function and social cognition are integrated across broad suites of interlinked and overlapping cerebral regions. Moreover, a diverse palette of neuromodulators, including acetylcholine, cytokines, and brain-derived neurotrophic factor (BDNF), influence cognitive performance.
Pharmacotherapy does not target cerebral circuits perse; rather, it targets G protein-coupled receptors (GPCRs), ion channels, transporters, and other proteins involved in the actions of neuromodulators. These molecular substrates of cognition constitute a vast repertoire of potential drug targets for countering cognitive impairment in psychiatric disorders.
Representing a level of integration that is intermediate between cells and cerebral circuits, neurons do not generally act in isolation; rather, they operate as synchronized and rhythmically active assemblies to encode, transmit and modulate information underpinning cognitive function.
- Disruption of cerebral networks as a cause of cognitive impairment
Cognitive deficits observed in schizophrenia have long been ascribed to reduced activation of the dorsolateral PFC (known as hypofrontality) but many cortical and subcortical structures are also affected, with a complex pattern of region-dependent hypo- or hyperactivation, increased activity may reflect an attempt to compensate for insufficient performance. Cognitive impairment in psychiatric disorders is characterized by a complex pattern of disconnection and over connection. An important issue, therefore, is whether the circuits controlling cognition can be reconstituted once they are disrupted, as certain structural perturbations may be irreversible.
- Genetic risk factors for cognitive deficits in psychiatric disorders
First, although psychiatric disorders have a moderate to high heritability, genetic risk factors are numerous and only have a small effect; they show low penetrance and epistasis. Second, if a mutation, deletion, or other genetic defect is associated with a psychiatric disorder, this does not necessarily indicate a role in the induction of cognitive impairment. Third, even if a genetic defect is implicated in the pathological mechanisms that lead to cognitive impairment, it is not an appropriate target for their alleviation. Fourth, some plasticity-related genes predispose individuals to cognitive deficits under adverse developmental conditions but have the opposite effect in a favorable environment. Last, the limited success of even genome-wide studies in finding genes that are major risk factors may also be ascribed to additional layers that can epigenetically control mask the effects of genetic defects.
Strategies to Counter Cognitive Impairment
- Direct and indirect modulation of cognitive performance by pharmacotherapy
- Limited clinical feedback
- Complex effects on cognition: bell-shaped dose-response curves
- Normalization of pathological processes versus symptomatic strategies
- Domain-specific and generalized improvements in cognitive performance
- Intracellular targets
- Neurogenesis
- Epigenetics
- Modulation of miRNA-controlled neural circuits
- Coupling pharmacotherapy with alternative strategies
Clinical Development of Pro-cognitive Agents
Clinical studies of pro-cognitive agents can now use various techniques with experimental counterparts for estimating optimal drug doses for efficacy, tracking cognitive actions in a manner complementary to behavioral rating scales, improving stratification of patients for drug trials, and exploring cerebral mechanisms of pro-cognitive properties.
As there is no unitary cause of cognitive impairment, and no single solution for its control, many promising lines of research should be pursued. At Creative Biolabs, we have the expertise to optimize each stage in neurosciences research, particularly with a focus on the study of cognitive dysfunction in psychiatric disorders. We ensure that you get your desired outcome and achieve the highest level of efficiency throughout. Please feel free to contact us.
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)